For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...
Medpage Today on MSN4d
Survival Win for Pembrolizumab in Early Triple-Negative Breast CancerPD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
4don MSN
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...
Opens in a new tab or window Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to clinically meaningful improvement in progression-free survival (PFS) compared with ...
Ivonescimab improved PFS when compared to pembrolizumab as first-line therapy in patients with advanced NSCLC in the phase 3 HARMONi-2 trial.
In the ITT population, ivonescimab demonstrated a clinically meaningful mPFS of 11.15 months vs. 5.82 months with pembrolizumab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback